Choose a country to view content specific to your location
Choose a country to view content specific to your location
Paul Granato, Ph.D., DABMM, FAAM, presents comprehensive review of Campylobacter, including modes of transmission, symptoms, and virulence factors. This program will also discuss the advantages and disadvantages of the different test methods currently available.
Speaker: Paul Granato, Ph.D., DABMM, FAAM. Professor of Pathology and Microbiology, SUNY Upstate Medical University, Director of Microbiology Laboratory Alliance of Central New York, Syracuse, New York Consultant Clinical Microbiologist Centrex Clinical Laboratories, Utica, New York.
Renowned gastroenterologists Dr. Steven F. Moss (Brown University) and Dr. Colin W. Howden (University of Tennessee) will review the latest recommendations on who, how, and when to test for H. pylori, including newly identified patient groups. They will also discuss a clinical case on managing infection.
The program covers prevalence, key disease associations, current non-invasive testing guidance, and updated treatment strategies, highlighting the “Test–Treat–Retest” approach to improve patient outcomes.
Speaker: Dr. Steven Moss and Dr. Colin Howden
The COVID-19 pandemic has left a lasting impact on diagnostic immunoassays, with emerging evidence linking SARS-CoV-2 infection to increased antibody-mediated immunoassay interference. This presentation explores the rise in interference, particularly from rheumatoid factor (Rf), and its implications for assay accuracy.
View this webinar to learn about:
The session also highlights the role of passive, active, and universal blockers in neutralizing interfering antibodies — and showcases Meridian Life Science’s solutions for ELISA, CLIA, and LFA platforms.
Speaker: John Francois, Product Manager
The COVID-19 pandemic has left a lasting impact on diagnostic immunoassays, with emerging evidence linking SARS-CoV-2 infection to increased antibody-mediated immunoassay interference. This presentation explores the rise in interference, particularly from rheumatoid factor (Rf), and its implications for assay accuracy.
View this webinar to learn about:
The session also highlights the role of passive, active, and universal blockers in neutralizing interfering antibodies — and showcases Meridian Life Science’s solutions for ELISA, CLIA, and LFA platforms.
Speaker: John Francois, Product Manager
Meridian offers diagnostic manufacturers the complete solution with over 3,000 antigens and antibodies covering more than 500 diseases and an extensive range of specialty qPCR/RT-qPCR master mixes and molecular enzymes all manufactured under ISO13485 regulations.
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
